lyophilized powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
In early medieval Europe, some accounts stated that Common Vervain was used to staunch Jesus' wounds after his removal from the cross; hence names like "Holy Herb" or (e.g. in Wales) "Devil's bane". Because of the association with the Passion of Christ, it came to be used in ointments to drive out and repel "demonic" illnesses. Vervain flowers are engraved on cimaruta, Italian anti-stregheria charms. In the 1870 The History and Practice of Magic by "Paul Christian" (Jean-Baptiste Pitois) it is employed in the preparation of a mandragora charm. A Royal Navy Arabis-class sloop of the World War I era was named HMS Verbena, and in World War II a Group 1 Flower-class corvette bore the same name; a Group 2 vessel of the latter class was called HMS Vervain. The only Verbena widely found in England in a wild state is common vervain, though it is just as possible that the names reference the popular ornamental verbenas, such as the garden vervain.
=== Substrate concentrations === The remaining enzymes of the cycle are controlled by the concentrations of their substrates. Thus, inherited deficiencies in cycle enzymes other than ARG1 do not result in significant decreases in urea production (if any cycle enzyme is entirely missing, death occurs shortly after birth). Rather, the deficient enzyme's substrate builds up, increasing the rate of the deficient reaction to normal. The anomalous substrate buildup is not without cost, however. The substrate concentrations become elevated all the way back up the cycle to NH+4, resulting in hyperammonemia (elevated [NH+4]P). Although the root cause of NH+4 toxicity is not completely understood, a high [NH+4] puts an enormous strain on the NH+4-clearing system, especially in the brain (symptoms of urea cycle enzyme deficiencies include intellectual disability and lethargy). This clearing system involves GLUD1 and GLUL, which decrease the 2-oxoglutarate (2OG) and Glu pools. The brain is most sensitive to the depletion of these pools. Depletion of 2OG decreases the rate of TCAC, whereas Glu is both a neurotransmitter and a precursor to GABA, another neurotransmitter.
General Public were an English new wave band, formed in Birmingham in 1983, by vocalists Dave Wakeling and Ranking Roger of the Beat, and which also included former members of Dexys Midnight Runners, the Specials, and the Clash. They are best remembered for their hits "Tenderness" (1984) and "I'll Take You There" (1994).
=== Lactic acidosis === A randomized controlled trial in children with congenital lactic acidosis found that while DCA was well tolerated, it was ineffective in improving clinical outcomes. A separate trial of DCA in children with MELAS (a syndrome of inadequate mitochondrial function, leading to lactic acidosis) was halted early, as all 15 of the children receiving DCA experienced significant nerve toxicity without any evidence of benefit from the medication. A randomized controlled trial of DCA in adults with lactic acidosis found that while DCA lowered blood lactate levels, it had no clinical benefit and did not improve hemodynamics or survival. Thus, while early case reports and pre-clinical data suggested that DCA might be effective for lactic acidosis, subsequent controlled trials have found no clinical benefit of DCA in this setting. In addition, clinical trial subjects were incapable of continuing on DCA as a study medication owing to progressive toxicities.
Mescaline, also known in chemical terms as 3,4,5-trimethoxyphenethylamine, is a naturally occurring psychedelic drug and alkaloid of the phenethylamine and scaline families found in certain cacti like peyote (Lophophora williamsii) and the San Pedro cactus (Echinopsis pachanoi, others). The drug is used recreationally, spiritually, and medically, with psychedelic effects occurring at doses of 100 to 800 mg (as its hydrochloride salt) orally and it can be used in pure form or in the form of mescaline-containing cacti. Mescaline induces a psychedelic experience characterized by visual changes, altered perception of time, space, and self, synesthesia, and spiritual experiences, with an onset of 30 to 60 minutes, a time to peak of 2 to 4 hours, and a duration that increases with dose and ranges from 6 to 14 hours. Mescaline primarily acts as a partial agonist at serotonin 5-HT2A receptors, with varying affinity and efficacy across multiple other receptors and targets. The serotonin 5-HT2A receptor antagonist ketanserin blocks mescaline's psychoactive effects. Mescaline is a relatively hydrophilic compound structurally related to dopamine, first synthesized in 1919, with numerous synthetic methods and potent analogues developed since. It occurs naturally in various cacti species, with concentrations varying widely, and is biosynthesized in plants from amino acids like phenylalanine and tyrosine. The practice of humans consuming mescaline-containing cacti dates back over 6,000 years.
Sources: en.wikipedia.org
=== Mass spectrometry of metallocenes === Mass spectrometry of metallocene complexes has been very well studied and the effect of the metal on the fragmentation of the organic moiety has received considerable attention and the identification of metal-containing fragments is often facilitated by the isotope distribution of the metal. The three major fragments observed in mass spectrometry are the molecular ion peak, [C10H10M]+, and fragment ions, [C5H5M]+ and M+.
== Competitors == Major competitors in the United States include the United States Postal Service (USPS), FedEx, and Amazon Logistics, along with regional carriers such as OnTrac, and LSO (formerly Lonestar Overnight). In addition to these domestic carriers, UPS competes with a variety of international operators, including SF Express, Canada Post (and its subsidiary Purolator), TransForce, Deutsche Post (and its subsidiary DHL), La Poste (France) (and its subsidiary Chronopost), Royal Mail, Japan Post Service, and many other regional carriers, national postal services and air cargo handlers. Historically, the bulk of competition for UPS came from inexpensive ground-based delivery services, such as Parcel Post (USPS) or Choice Logistics. In 1998, FedEx expanded into ground parcel delivery through its acquisition of RPS (formerly Roadway Package System), rebranding it as FedEx Ground in 2000. In 2003, DHL acquired Airborne Express, expanding its operations in the United States. In response to the expansion of FedEx and DHL, UPS partnered with the US Postal Service to offer UPS Mail Innovations, a program that allows UPS to pick up mail and packages weighing under one pound separately from the main ground network and transfer them to a USPS center, or destination delivery unit (DDU), for final distribution. This process is also known as zone skipping, long used by parcel consolidators.
This ended relations between Mexico and Germany, which had been weakening since the British commercial blockade against the Axis. Simultaneously, Mexico resumed diplomatic relations with the United Kingdom, which had been broken since the oil expropriation of 1938.
== Drug pricing issue and exit in the Swiss market == In July 2025, Roche withdrew Lunsumio from the Swiss market following failed price negotiations with the Swiss Federal Office of Public Health (BAG). The drug had been available since February 2023 through a special "Early Access" program that allowed reimbursement before complete clinical data was available. Under this arrangement, Roche initially covered treatment costs until efficacy was demonstrated, after which the remaining therapy could exceed 100,000 Swiss francs. When Swissmedic extended the temporary authorization in February 2025 due to still-missing complete clinical data from Phase III studies, Roche rejected the previously negotiated pricing model and demanded higher prices. The BAG refused to modify the agreement, citing concerns that exceptions would set a precedent for other pharmaceutical companies and demanding additional efficacy evidence despite the drug showing positive effects in Phase II studies. According to Swissmedic pricing data, a single 60-mg dose (two vials) of Lunsumio costs over 7,000 Swiss francs. The withdrawal was announced to oncologists on July 1, 2025, affecting approximately 24 patients annually who suffer from follicular lymphoma—a slowly progressing cancer of the lymph nodes with about 500 new cases per year in Switzerland. Roche also refused to provide individual case reimbursements—a standard Swiss mechanism for exceptional medical situations.
The N-terminal methionine usually found after translation has an N-terminus blocked with a formyl group. This formyl group (and sometimes the methionine residue itself, if followed by Gly or Ser) is removed by the enzyme deformylase. pyroglutamate
Sources: en.wikipedia.org
=== Formation of reactive oxygen compounds === Tuftsin augments the formation of O2− and H2O2 to a considerable extent without the need for particle phagocytosis. Experiments showed rapid response to various concentrations of tuftsin. The optimum concentration was at 375 nM. This response to tuftsin stimulation of macrophage accounts for about 90% of the superoxide formed through the xanthine oxidase system.
The architecture of Brazil is influenced by Europe, especially Portugal. It has a history that goes back 500 years to the time, when Pedro Álvares Cabral landed in Brazil in 1500. Portuguese colonial architecture was the first wave of architecture to go to Brazil. It is the basis for all Brazilian architecture of later centuries. In the 19th century, during the time of the Empire of Brazil, the country followed European trends and adopted Neoclassical and Gothic Revival architecture. Then, in the 20th century, especially in Brasília, Brazil experimented with modernist architecture. The colonial architecture of Brazil dates to the early 16th century, when Brazil was first explored, conquered and settled by the Portuguese. The Portuguese built architecture familiar to them in Europe in their aim to colonize Brazil. They built Portuguese colonial architecture, which included churches and civic architecture, including houses and forts, in Brazilian cities and the countryside. During the 19th century, Brazilian architecture saw the introduction of more European styles to Brazil, such as Neoclassical and Gothic Revival architecture. This was usually mixed with Brazilian influences from their own heritage. In the 1950s modernist architecture was introduced when Brasília was built as a new federal capital in the interior of Brazil to help develop the interior. The architect Oscar Niemeyer idealized and built government buildings, churches and civic buildings in the modernist style.
==== Prevention of psychosis and symptom improvement ==== Test batteries such as the PACE (Personal Assessment and Crisis Evaluation Clinic) and COPS (Criteria of Prodromal Syndromes), which measure low-level psychotic symptoms and cognitive disturbances, are used to evaluate people with early, low-level symptoms of psychosis. Test results are combined with family history information to identify patients in the "high-risk" group; they are considered to have a 20–40% risk of progression to frank psychosis within two years. These patients are often treated with low doses of antipsychotic drugs with the goal of reducing their symptoms and preventing progression to frank psychosis. While generally useful for reducing symptoms, clinical trials to date show little evidence that early use of antipsychotics improves long-term outcomes in those with prodromal symptoms, either alone or in combination with cognitive-behavioral therapy.
== History == Thiotepa and its synthesis were patented in 1952 by the American Cyanamid company. It was made for use in the textile industry and in the production process of plastics. However, thiotepa entered human trials in 1953 and was found to be effective against acute myeloid leukemia, chronic myelogenous leukemia, and Hodgkin's lymphoma. The first clinical trial noted a "reasonable margin for safety" between the apparent dose and undesired bone marrow suppression In January 2007, the European Medicines Agency (EMA) designated thiotepa as an orphan drug. In April 2007, the United States FDA designated thiotepa as a conditioning treatment for use prior to hematopoietic stem cell transplantation. In June 2024, the FDA approved a ready-to-dilute liquid formulation of thiotepa to treat breast and ovarian cancer.
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
Bremelanotide binds several melanocortin receptors, and MC4R is the subtype most often cited as responsible for its behavioural effects. Activity at MC1R, MC3R and MC5R is also reported. Selectivity is therefore described as limited rather than precise.